在冠状动脉再血管化后停止使用他类药物
Ko Yamamoto1, Takeshi Morimoto2, Masahiro Natsuaki3
1Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
The American journal of cardiology
|October 5, 2023
概括
大约五分之一的冠状动脉疾病患者在冠状动脉再血管化后停止使用他类药物治疗. 由于不坚持或副作用导致的停用他类药物,在现实实践中显著增加了随后的死亡风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 立方体治疗对于治疗冠状动脉疾病 (CAD) 是至关重要的.
- 在冠状动脉复血管化后的患者中停止使用他类药物的现实数据很少.
- 了解停止治疗的原因对于患者的治疗结果至关重要.
研究的目的:
- 评估冠状动脉再血管化后患者中断他类药物的发生率和原因.
- 评估停用他类药物与随后的死亡率之间的关联.
主要方法:
- 分析了来自CREDO-京都注册表队列-3的11,144名患者,他们接受了第一次冠状动脉再血管化,并正在服用他类药物.
- 停止使用他类药物定义为至少两个月停止使用.
- 平均随访时间为6年.
主要成果:
- 在7年内,停止使用他类药物的累积发病率达到21.4%.
- 主要原因包括不遵守 (2.35 HR),副作用 (2.48 HR) 和并发症恶化 (22.08 HR).
- 停药与死亡率 (3.54 HR) 的增加密切相关.
结论:
- 在冠状动脉再血管化后,切断实体世界中的他类药物是常见的,在7年内影响近五分之一的患者.
- 不坚持,副作用和并发症恶化是主要的驱动因素.
- 停药显著增加死亡风险,强调了需要坚持支持的需要.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
681
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
681
Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Acute Coronary Syndrome I: Introduction
30
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
30
Acute Coronary Syndrome III: Diagnostic Studies
9
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
9


